- bluebird bio, Inc.

Media Contacts

Sarah Alspach

Chief Communications Officer

(857) 299-6198

sarah.alspach@bluebirdbio.com
Jess Rowlands

Senior Director, Product Communications

(857) 299-6103

jess.rowlands@bluebirdbio.com

Investor Contacts

Courtney O’Leary

Investor Relations

(978) 621-7347

coleary@bluebirdbio.com

bluebird bio Completes Planned Business Separation

Read more about bluebird bio Completes Planned Business Separation

Najoh Tita-Reid

Najoh Tita-Reid

Director

Andrew Obenshain

Andrew Obenshain

Director

Nick Leschly

Nick Leschly

Director

Lis Leiderman

Lis Leiderman

Director

Financial Expert

bluebird bio Sets Record Date and Distribution Date for Planned Business Separation

Read more about bluebird bio Sets Record Date and Distribution Date for Planned Business Separation

bluebird bio Provides Update on Upcoming Planned Business Separation

Read more about bluebird bio Provides Update on Upcoming Planned Business Separation

bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions

Read more about bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions

2seventy bio Announces Upcoming Investor Events

Read more about 2seventy bio Announces Upcoming Investor Events

bluebird bio Secures $75 Million in Private Placement Equity Financing

Read more about bluebird bio Secures $75 Million in Private Placement Equity Financing